Molecular Medicine : 5th tranche of the share capital increase reserved to Société Générale (“SEF") completed

PRESS RELEASE

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

MolMed: completed the fifth tranche of the share capital increase to be reserved to Société Générale pursuant to "SEF - Standby Equity Facility" agreement

Milan, May 25, 2018 - Following the press release disclosed to the market on May 24, 2018, MolMed S.p.A. (MLMD.MI) ("MolMed" or the "Company") announces the settlement of the fifth tranche (the "Fifth Tranche") of the share capital increase against payment, in one or more tranches, in divisible form, to be executed by and no later than 31 October 2018, without pre-emptive rights pursuant to Article 2441, fourth paragraph, second sentence of the Italian Civil Code reserved to Société Générale ("SG") pursuant to the agreement named "SEF - Standby Equity Facility" executed on 6 October 2016 between the Company and SG (the "SEF Agreement"). The name "SEF - Standby Equity Facility" is an exclusive trade name of SG.

Pursuant to the SEF Agreement and in respect of the Fifth Tranche, SG has undertaken to subscribe no. 6,488,279 MolMed ordinary shares, equal to 1.40% of the Company's share capital, at a price equal to Euro 0.4789 per share (of which Euro 0.0471 represents capital and the remainder represents share premium), for a total amount of Euro 3,107,237.

Therefore, the Company has issued today no. 6,488,279 ordinary shares against payment of the relevant consideration by SG completing the execution of the share capital increase related to the indicated SEF Agreement.

The new share capital of MolMed will be equal to Euro 21,819,020.83 divided into no. 463,450,672 ordinary shares with no par value.

The execution of the SEF Agreement will enable the Company to find resources, by benefiting from the flexibility of such tool, to satisfy the Company's periodic liquidity needs, as well as to contribute to the development of the industrial plans, over the term of 24 months of the SEF Agreement.

Pursuant to the SEF Agreement, SG is not subject to any lock-up on the Shares and the Company has not executed any agreement with SG for the resale of such Shares on the market. No stock lending agreement or guarantee on the Shares is in place between SG and the Company.

The Shares issued in relation to the Fifth Tranche, together with any ordinary shares issued in the 12 months preceding the date of the utilization request, do not exceed 20% of MolMed's ordinary shares already admitted to trading on the Italian Stock Exchange on the date of the relevant Utilization Request and, therefore, the Fifth Tranche of the share capital increase is exempt from the obligation to publish a listing prospectus, pursuant to Article 1, paragraph 5, section 1, let. a) of the regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017.

This press release is written in compliance with public disclosure obligations established by Consob's (Italian securities & exchange commission) Issuers Regulation.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone [phone] - Fax [phone]- www.molmed.com

Share capital € 20,949,084.36 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

About MolMed

PRESS RELEASE

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. OpenZone.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

phone: [phone] fax: [phone] e-mail:[e-mail]

FROM GENES TO THERAPY

Marcella Ruggiero Press Agent

SEC Relazioni Pubbliche e Istituzionali s.r.l. phone: [phone] cellulare: [phone] e-mail:[e-mail]